A novel sodium benzoate analog (CH-1) decreases blood ammonia levels in experimental hyperammonemia

Octavio Campollo, Ruben Cortez, Alberto M Odor, Rosa Maria Muñoz, Juan Armendariz-Borunda, Javier Alvarez-Tostado

Research output: Contribution to journalArticle

Abstract

Sodium benzoate has been used for the treatment of congenital hyperammonemic syndromes and hepatic encephalopathy for its ammonia lowering effect. A zinc-derivative of sodium benzoate (CH-1) with similar effects, is presented herein. We administered CH-1 at doses of 250, 500 and 1000 mg/kg body weight during 7 days to male Wistar rats after a portocaval shunt operation was performed as a model for experimental hyperammonemia. There was a decrease in blood ammonia levels in all groups receiving CH-1. A linear relationship (r=-0.487, P < 0.01) was observed between the dose of CH-1 and blood ammonia levels. The effective dose 50 (ED50) was 320 mg/kg body weight (95% C.I. 176-581 mg) with a slope of 1.538 (Litchfield and Wilcoxon method). These results suggest that benzoic acid salts such as CH-1 may prove a new alternative for the treatment of hyperammonemia. Potential advantages of non-sodium salts of benzoic acid are discussed.

Original languageEnglish (US)
Pages (from-to)104-109
Number of pages6
JournalHepatology Research
Volume15
Issue number2
DOIs
StatePublished - Jul 1999
Externally publishedYes

Fingerprint

Sodium Benzoate
Hyperammonemia
Ammonia
Benzoic Acid
Salts
Body Weight
Hepatic Encephalopathy
Ketamine
Wistar Rats
Zinc
Theoretical Models
Therapeutics

Keywords

  • Hepatic encephalopathy
  • Hyperammonemia
  • Pharmacology
  • Sodium benzoate
  • Treatment
  • Zinc

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Campollo, O., Cortez, R., Odor, A. M., Maria Muñoz, R., Armendariz-Borunda, J., & Alvarez-Tostado, J. (1999). A novel sodium benzoate analog (CH-1) decreases blood ammonia levels in experimental hyperammonemia. Hepatology Research, 15(2), 104-109. https://doi.org/10.1016/S1386-6346(99)00016-9

A novel sodium benzoate analog (CH-1) decreases blood ammonia levels in experimental hyperammonemia. / Campollo, Octavio; Cortez, Ruben; Odor, Alberto M; Maria Muñoz, Rosa; Armendariz-Borunda, Juan; Alvarez-Tostado, Javier.

In: Hepatology Research, Vol. 15, No. 2, 07.1999, p. 104-109.

Research output: Contribution to journalArticle

Campollo, O, Cortez, R, Odor, AM, Maria Muñoz, R, Armendariz-Borunda, J & Alvarez-Tostado, J 1999, 'A novel sodium benzoate analog (CH-1) decreases blood ammonia levels in experimental hyperammonemia', Hepatology Research, vol. 15, no. 2, pp. 104-109. https://doi.org/10.1016/S1386-6346(99)00016-9
Campollo, Octavio ; Cortez, Ruben ; Odor, Alberto M ; Maria Muñoz, Rosa ; Armendariz-Borunda, Juan ; Alvarez-Tostado, Javier. / A novel sodium benzoate analog (CH-1) decreases blood ammonia levels in experimental hyperammonemia. In: Hepatology Research. 1999 ; Vol. 15, No. 2. pp. 104-109.
@article{34c7af4ee22a42b7a7d7a5fce4ce8667,
title = "A novel sodium benzoate analog (CH-1) decreases blood ammonia levels in experimental hyperammonemia",
abstract = "Sodium benzoate has been used for the treatment of congenital hyperammonemic syndromes and hepatic encephalopathy for its ammonia lowering effect. A zinc-derivative of sodium benzoate (CH-1) with similar effects, is presented herein. We administered CH-1 at doses of 250, 500 and 1000 mg/kg body weight during 7 days to male Wistar rats after a portocaval shunt operation was performed as a model for experimental hyperammonemia. There was a decrease in blood ammonia levels in all groups receiving CH-1. A linear relationship (r=-0.487, P < 0.01) was observed between the dose of CH-1 and blood ammonia levels. The effective dose 50 (ED50) was 320 mg/kg body weight (95{\%} C.I. 176-581 mg) with a slope of 1.538 (Litchfield and Wilcoxon method). These results suggest that benzoic acid salts such as CH-1 may prove a new alternative for the treatment of hyperammonemia. Potential advantages of non-sodium salts of benzoic acid are discussed.",
keywords = "Hepatic encephalopathy, Hyperammonemia, Pharmacology, Sodium benzoate, Treatment, Zinc",
author = "Octavio Campollo and Ruben Cortez and Odor, {Alberto M} and {Maria Mu{\~n}oz}, Rosa and Juan Armendariz-Borunda and Javier Alvarez-Tostado",
year = "1999",
month = "7",
doi = "10.1016/S1386-6346(99)00016-9",
language = "English (US)",
volume = "15",
pages = "104--109",
journal = "International Hepatology Communications",
issn = "0928-4346",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - A novel sodium benzoate analog (CH-1) decreases blood ammonia levels in experimental hyperammonemia

AU - Campollo, Octavio

AU - Cortez, Ruben

AU - Odor, Alberto M

AU - Maria Muñoz, Rosa

AU - Armendariz-Borunda, Juan

AU - Alvarez-Tostado, Javier

PY - 1999/7

Y1 - 1999/7

N2 - Sodium benzoate has been used for the treatment of congenital hyperammonemic syndromes and hepatic encephalopathy for its ammonia lowering effect. A zinc-derivative of sodium benzoate (CH-1) with similar effects, is presented herein. We administered CH-1 at doses of 250, 500 and 1000 mg/kg body weight during 7 days to male Wistar rats after a portocaval shunt operation was performed as a model for experimental hyperammonemia. There was a decrease in blood ammonia levels in all groups receiving CH-1. A linear relationship (r=-0.487, P < 0.01) was observed between the dose of CH-1 and blood ammonia levels. The effective dose 50 (ED50) was 320 mg/kg body weight (95% C.I. 176-581 mg) with a slope of 1.538 (Litchfield and Wilcoxon method). These results suggest that benzoic acid salts such as CH-1 may prove a new alternative for the treatment of hyperammonemia. Potential advantages of non-sodium salts of benzoic acid are discussed.

AB - Sodium benzoate has been used for the treatment of congenital hyperammonemic syndromes and hepatic encephalopathy for its ammonia lowering effect. A zinc-derivative of sodium benzoate (CH-1) with similar effects, is presented herein. We administered CH-1 at doses of 250, 500 and 1000 mg/kg body weight during 7 days to male Wistar rats after a portocaval shunt operation was performed as a model for experimental hyperammonemia. There was a decrease in blood ammonia levels in all groups receiving CH-1. A linear relationship (r=-0.487, P < 0.01) was observed between the dose of CH-1 and blood ammonia levels. The effective dose 50 (ED50) was 320 mg/kg body weight (95% C.I. 176-581 mg) with a slope of 1.538 (Litchfield and Wilcoxon method). These results suggest that benzoic acid salts such as CH-1 may prove a new alternative for the treatment of hyperammonemia. Potential advantages of non-sodium salts of benzoic acid are discussed.

KW - Hepatic encephalopathy

KW - Hyperammonemia

KW - Pharmacology

KW - Sodium benzoate

KW - Treatment

KW - Zinc

UR - http://www.scopus.com/inward/record.url?scp=0032818053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032818053&partnerID=8YFLogxK

U2 - 10.1016/S1386-6346(99)00016-9

DO - 10.1016/S1386-6346(99)00016-9

M3 - Article

AN - SCOPUS:0032818053

VL - 15

SP - 104

EP - 109

JO - International Hepatology Communications

JF - International Hepatology Communications

SN - 0928-4346

IS - 2

ER -